ERBB2 and undifferentiated carcinoma: In contrast, type II tumours, including high-grade serous and undifferentiated carcinomas characterised by p53 mutations and overexpression/amplification of HER-2/neu and AKT2, tend to show a highly aggressive behaviour (Shih and Kurman, 2004; Bell, 2005).